Financial Performance - The company's operating revenue for Q1 2025 was ¥187,143,844.02, a decrease of 20.87% compared to ¥236,493,578.79 in the same period last year[4] - The net profit attributable to shareholders was -¥9,813,367.88, representing a decline of 129.95% from -¥4,267,655.29 year-on-year[4] - The total profit decreased by 316.45% to -¥5,019,886.71, primarily due to increased promotional expenses[10] - Net profit for the period was a loss of ¥8,691,993.76 compared to a loss of ¥3,235,770.32 in the previous period, representing a worsening of approximately 168.5%[20] - Basic and diluted earnings per share were both -0.0464, compared to -0.0202 in the previous period[21] Cash Flow - The net cash flow from operating activities improved to ¥5,414,125.34, a significant increase of 111.64% compared to -¥46,510,683.15 in the previous year[4] - Cash inflow from operating activities totaled 292,722,242.47, compared to 232,709,896.78 in the prior period, reflecting an increase of approximately 25.8%[23] - Cash outflow from operating activities was 287,308,117.13, up from 279,220,579.93, indicating a rise of about 2.0%[23] - The company received 59,322,022.12 in cash related to operating activities, a substantial increase from 1,714,780.18 in the previous period[23] - The company paid 6,160,425.34 in taxes, which is an increase from 4,897,410.48 in the prior period, reflecting a rise of approximately 25.8%[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,048,145,510.01, down 5.29% from ¥1,106,685,362.58 at the end of the previous year[4] - Total current assets decreased from CNY 622,216,232.95 to CNY 573,782,308.15[17] - Total liabilities decreased to ¥512,390,201.69 from ¥562,238,060.50, a decline of approximately 8.9%[19] - The company's equity attributable to shareholders decreased to ¥412,672,707.21 from ¥422,486,075.09, a decrease of about 2.0%[19] Research and Development - Research and development expenses decreased by 69.35% to ¥1,000,000, primarily due to reduced R&D spending by the subsidiary[9] - Research and development expenses decreased to ¥457,471.32 from ¥1,492,530.81, a reduction of approximately 69.3%[20] Investments and Subsidiaries - Investment income increased by 119.53% to ¥12,900,000, attributed to the subsidiary's turnaround in profitability[9] - The company plans to establish a joint venture with Beiyinmei Co., Ltd. to set up Xinjiang Tianshan Xiaobei Food Sales Co., Ltd. with a registered capital of CNY 1 million, where Tianshan Yunmu Dairy will hold 95%[15] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period was 26,787, with no preferred shareholders[14] - The largest shareholder, Xinjiang Tiande Biological Co., Ltd., holds 41.82% of the shares, totaling 88,378,171 shares[14] Government Subsidies - The company received government subsidies totaling ¥2,234,639.22, which positively impacted the financial results[5] - Cash flow from operating activities increased by CNY 51,924,808.49, a growth of 111.64% compared to the same period last year, primarily due to government subsidies received by subsidiaries[12] - Net increase in cash and cash equivalents rose by CNY 50,560,250.70, representing an 86.81% increase year-on-year, mainly attributed to government subsidies received by subsidiaries[12] Other Financial Metrics - The cash flow statement details are not provided, indicating a need for further analysis in future reports[22] - The company reported an increase in contract liabilities to ¥28,248,795.13 from ¥9,941,931.44, an increase of approximately 184.5%[20] - The net cash flow from investing activities was -4,998,298.00, worsening from -4,327,664.79 in the previous period[24] - The total cash and cash equivalents at the end of the period were 238,852,718.80, down from 248,925,109.68, a decrease of about 4.3%[24]
西部牧业(300106) - 2025 Q1 - 季度财报